Haven't posted here much lately for those who monitor this board a couple of things from the Q3 call/PR: 1-GALNS data before thanksgiving 2-PARP program doesn't get much press but it could advance to Phase 3 in as early as end of '13 which is quite fast! That would likely be for BRCA mutations. 3-Pompe program has fully enrolled (16) patients in the highest dosing cohort (20mg/kg) and data is expected in Q1 '13.
Market Data 
Markets 
AI
